Thymidylate Synthase Expression in Normal Colonic Mucosa: A Predictive Marker of Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Adjuvant Chemotherapy

Oncology ◽  
2004 ◽  
Vol 67 (2) ◽  
pp. 135-142 ◽  
Author(s):  
Daniele Santini ◽  
Bruno Vincenzi ◽  
Giuseppe Perrone ◽  
Carla Rabitti ◽  
Domenico Borzomati ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Colonic Mucosa ◽  
Predictive Marker ◽  
Normal Colonic Mucosa ◽  
Colorectal Cancer Patients

Assessment of vitamin D and VDR gene expression in colorectal cancer patients

2015 ◽  
Vol 51 (3) ◽  
pp. 193-198
Author(s):  
Joanna Berska ◽  
Jolanta Bugajska ◽  
Diana Hodorowicz-Zaniewska ◽  
Krystyna Sztefko
Keyword(s):  
Colorectal Cancer ◽  
Vitamin D ◽  
Serum Concentration ◽  
Cancer Patients ◽  
Colonic Mucosa ◽  
Tumor Tissue ◽  
Disease Stage ◽  
Control Group ◽  
Normal Colonic Mucosa ◽  
Colorectal Cancer Patients

Background: Vitamin D insufficiency may increase risk and/or progression of cancer. Vitamin D acts through a nuclear receptor (VDR) which binding to vitamin D response elements causes changes in many genes expression. The aim: to assess the serum concentration of 25-hydroxycholecalciferol (25(OH)D3) and tissue VDR expression in colorectal cancer patients in relation to disease stage, tumor localization and disease progression. Material & Methods: The study group consisted of 39 patients with colorectal cancer (mean age 65,5±6,8 yrs, 23/16 male/female) and a control group consisted of 25 patients (mean age 51,0±6,9 yrs; 8/17 male/female) without gastrointestinal disease and without neoplasm. Serum level of 25(OH)D3 was measured by HPLC/UV. RNA was isolated from homogenized normal colonic mucosa and tumor tissue then RT-PCR was performed. Results: The mean serum concentration of 25(OH)D3 was lower in the colorectal cancer patients as compared to the control group. The difference was significantly lower only for the patients with the early stages of the disease (p<0.02) and for the patients with tumor present in rectum (p<0.03). Higher VDR expression in tumor tissue than in normal colonic mucosa was observed. For the patients with the early stages of the disease (stage A, B1, B2) higher expression of VDR as compared to the patients with advanced stages (stage C1, C2, D) was noticed. Moreover, VDR expression was higher in tumor tissue obtained from disease-free patients as compared to the patients with disease progression noted one-year-follow-up (p<0.04). Conclusion: Antitumor effect of vitamin D depends on VDR expression in tumor tissue.

Neutrophil/lymphocyte Ratio after Flow Citometry Periferic Blood Cell Detection - Predictive Marker of Anastomotic Fistula in Colorectal Cancer Surgery

2020 ◽  
Vol 71 (6) ◽  
pp. 295-306
Author(s):  
Dumitru Radulescu ◽  
Vlad Dumitru Baleanu ◽  
Andrei Nicolaescu ◽  
Marius Lazar ◽  
Marius Bica ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Rectal Surgery ◽  
Predictive Marker ◽  
Fistula Formation ◽  
Cell Detection ◽  
Colon And Rectal Surgery ◽  
Optimal Value ◽  
Anastomotic Fistula ◽  
Colorectal Cancer Patients

Anastomotic fistula is a dreadful complication of colon and rectal surgery that can put life into danger, being common after colorectal surgery. The preoperative lymphocyte neutrophil ratio (NLR) is known as a prognostic marker for colorectal cancer patients. The existence of a predictive marker of anastomotic fistula in colorectal cancer patients is not fully undestood, so we proposed to investigate the utility of preoperative NLR as a predictor of anastomotic fistula formation. This study the Neutrophils and lymphocytes were detected from periferic blood using flow citometry. We retrospectively evaluated 161 patients with colorectal cancer, who were treated curatively, in which at least one anastomosis was performed, comparing NLR values between patients who had fistula and those with normal healing, then comparing the group with low NLR, with the group with increased NLR, after finding the optimal value of NLR using the ROC curve.The optimal value of the NLR after establishing the cutoff value was 3.07. Between the low NLR group (n=134) and the high NLR group (n=27), were observed statistically significant differences in fistula (p [0.001) and death (p=0.001). The odds ratio for failure in the group with increased NLR was 10.37, which means that patients with NLR]3.54 have a chance of developing anastomotic fistula greater than 10.37 comparable to patients with lower NLR. We suggest the preoperative use of NLR can be used as a predictive marker of anastomotic fistula than can increase the quality of preoperative preparation and therefore the establishment of the optimal surgical technique that can lead to anastomotic fistula risk decrease.

Clinical and Socioeconomic Factors that Predict Non-completion of Adjuvant Chemotherapy for Colorectal Cancer in a Rural Cancer Center

2022 ◽  
pp. 000313482110547
Author(s):  
Chelsea Knotts ◽  
Alexandra Van Horn ◽  
Krysta Orminski ◽  
Stephanie Thompson ◽  
Jacob Minor ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Socioeconomic Factors ◽  
Cancer Patients ◽  
Private Insurance ◽  
Stage Ii ◽  
Stage Iii ◽  
Insurance Status ◽  
Complete Treatment ◽  
Colorectal Cancer Patients

Background Previous literature demonstrates correlations between comorbidities and failure to complete adjuvant chemotherapy. Frailty and socioeconomic disparities have also been implicated in affecting cancer treatment outcomes. This study examines the effect of demographics, comorbidities, frailty, and socioeconomic status on chemotherapy completion rates in colorectal cancer patients. Methods This was an observational case-control study using retrospective data from Stage II and III colorectal cancer patients offered chemotherapy between January 01, 2013 and January 01, 2018. Data was obtained using the cancer registry, supplemented with chart review. Patients were divided based on treatment completion and compared with respect to comorbidities, age, Eastern Cooperative Oncology Group (ECOG) score, and insurance status using univariate and multivariate analyses. Results 228 patients were identified: 53 Stage II and 175 Stage III. Of these, 24.5% of Stage II and 30.3% of Stage III patients did not complete chemotherapy. Neither ECOG status nor any comorbidity predicted failure to complete treatment. Those failing to complete chemotherapy were older (64.4 vs 60.8 years, P = .043). Additionally, those with public assistance or self-pay were less likely to complete chemotherapy than those with private insurance ( P = .049). Both factors (older age/insurance status) remained significant on multivariate analysis (increasing age at diagnosis: OR 1.03, P =.034; public insurance: OR 1.84, P = .07; and self-pay status: OR 4.49, P = .03). Conclusions No comorbidity was associated with failure to complete therapy, nor was frailty, as assessed by ECOG score. Though frailty was not significant, increasing age was, possibly reflecting negative attitudes toward chemotherapy in older populations. Insurance status also predicted failure to complete treatment, suggesting disparities in access to treatment, affected by socioeconomic factors.

Sign in / Sign up

Export Citation Format

Share Document